FUSION PROTEINS WITH TOXIC ACTIVITY - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 261

91. Nimmerjahn F, Ravetch JV. (2011) Fc g Rs in health and
disease. Curr. Top. Microbiol. Immunol. 350, 105-125.
92. Nagashima H, Ootsubo M, Fukazawa M, Motoi S,
Konakahara S, Masuho Y. (2011) Enhanced antibody-
dependent cellular phagocytosis by chimeric monoclonal
antibodies with tandemly repeated Fc domains. J. Biosci.
Bioeng. 111(4), 391-396.
93. Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais
JR. (2008) Optimization of antibody binding to
FcgammaRIIa enhances macrophage phagocytosis of tumor
cells. Mol. Cancer Ther. 7(8), 2517-2527.
94. Gelderman KA, Tomlinson S, Ross GD, Gorter A. (2004)
Complement function in mAb-mediated cancer immuno-
therapy. Trends Immunol. 25(3), 158-164.
95. Moore GL, Chen H, Karki S, Lazar GA. (2010) Engineered
Fc variant antibodies with enhanced ability to recruit
complement and mediate effector functions. MAbs 2(2),
181-189.
96. Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto
Y, Uchino A, et al. (2008) Mechanisms for cytotoxic effects of
anti-tumor necrosis factor agents on transmembrane tumor

necrosis factor alpha-expressing cells: comparison among
infliximab, etanercept, and adalimumab. Arthritis Rheum.
58(5), 1248-1257.
97. van Lookeren Campagne M, Wiesmann C, Brown EJ. (2007)
Macrophage complement receptors and pathogen clearance.
Cell. Microbiol. 9(9), 2095-2102.
98. ZhuW, SunM, Wang Y, Sun de J, Zhang S. (2011) Expression
and functional characterization of a recombinant targeted
toxin with an uPA cleavable linker in Pichia pastoris. Protein
Expr. Purif. 76(2), 184-189.
99. Holle L, Song W, Holle E, Wei Y, Li J, Wagner TE, et al.
(2009) In vitro- and in vivo-targeted tumor lysis by an MMP2
cleavable melittin-LAP fusion protein. Int. J. Oncol. 35(4),
829-835.
100. Kawamoto M, Horibe T, Kohno M, Kawakami K. (2011) A
novel transferrin receptor-targeted hybrid peptide disinte-
grates cancer cell membrane to induce rapid killing of cancer
cells. BMC Cancer 11, 359.
101. Kohno M, Horibe T, Haramoto M, Yano Y, Ohara K,
Nakajima O, et al. (2011) A novel hybrid peptide targeting
EGFR-expressing cancers. Eur. J. Cancer 47(5), 773-783.